[HTML][HTML] COVID-19, virology and geroscience: a perspective
C Vellas, P Delobel, PDS Barreto, J Izopet - The journal of nutrition, health …, 2020 - Elsevier
A new coronavirus, called SARS-CoV-2, was identified in Wuhan, China, in December 2019.
The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease …
The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease …
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management
L Wu, AM O'Kane, H Peng, Y Bi, D Motriuk-Smith… - Biochemical …, 2020 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of …
syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of …
The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19
Abstract The coronavirus disease (COVID-19) has once again reminded us of the
significance of host immune response and consequential havocs of the immune …
significance of host immune response and consequential havocs of the immune …
Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway
AR Daamen, P Bachali, KA Owen, KM Kingsmore… - Scientific reports, 2021 - nature.com
SARS-CoV2 is a previously uncharacterized coronavirus and causative agent of the COVID-
19 pandemic. The host response to SARS-CoV2 has not yet been fully delineated …
19 pandemic. The host response to SARS-CoV2 has not yet been fully delineated …
The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach
In this paper, a model is proposed of the pathophysiological processes of COVID-19 starting
from the infection of human type II alveolar epithelial cells (pneumocytes) by SARS-CoV-2 …
from the infection of human type II alveolar epithelial cells (pneumocytes) by SARS-CoV-2 …
Molecular mechanisms and therapeutic target of NETosis in diseases
J Huang, W Hong, M Wan, L Zheng - MedComm, 2022 - Wiley Online Library
Evidence shows that neutrophils can protect the host against pathogens in multiple ways,
including the formation and release of neutrophil extracellular traps (NETs). NETs are web …
including the formation and release of neutrophil extracellular traps (NETs). NETs are web …
COVID‐19 and non‐alcoholic fatty liver disease: two intersecting pandemics
P Portincasa, M Krawczyk, W Smyk… - European journal of …, 2020 - Wiley Online Library
Abstract Background Initial evidence from China suggests that most vulnerable subjects to
COVID‐19 infection suffer from pre‐existing illness, including metabolic abnormalities. The …
COVID‐19 infection suffer from pre‐existing illness, including metabolic abnormalities. The …
[HTML][HTML] Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
Methods: An open-label randomized clinical trial study was performed in Tabriz, North-West
of Iran. They were randomized to either the treatment with the bromhexine group or the …
of Iran. They were randomized to either the treatment with the bromhexine group or the …
[HTML][HTML] Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists
Dysregulated host immune responses drive mortality in pneumonia and acute respiratory
distress syndrome (ARDS) caused by a wide range of infections. In coronavirus disease …
distress syndrome (ARDS) caused by a wide range of infections. In coronavirus disease …
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with
inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of …
inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of …